Barrett, James E;
Jones, Allison;
Evans, Iona;
Herzog, Chiara;
Reisel, Daniel;
Olaitan, Adeola;
Mould, Tim;
... Widschwendter, Martin; + view all
(2023)
The WID-EC test for the detection and risk prediction of endometrial cancer.
International Journal of Cancer
, 152
(9)
pp. 1731-2015.
10.1002/ijc.34406.
![[thumbnail of Reisel_Intl Journal of Cancer - 2022 - Barrett - The WID‐EC test for the detection and risk prediction of endometrial cancer.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Reisel_Intl Journal of Cancer - 2022 - Barrett - The WID‐EC test for the detection and risk prediction of endometrial cancer.pdf Download (1MB) |
Abstract
The incidence of endometrial cancer is rising. Measures to identify women at risk and to detect endometrial cancer earlier are required to reduce the morbidity triggered by the aggressive treatment required for advanced endometrial cancer. We developed the WID-EC (Women's cancer risk IDentification-Endometrial Cancer) test, which is based on DNA methylation at 500 CpG sites, in a discovery set of cervical liquid-based cytology samples from 1,086 women with and without an endometrial cancer (217 cancer cases and 869 healthy controls) with a worse prognosis (grade 3 or ≥stage IB). We validated the WID-EC test in an independent external validation set of 64 endometrial cancer cases and 225 controls. We further validated the test in 150 healthy women (prospective set) who provided a cervical sample as part of the routine Swedish cervical screening programme, 54 of whom developed endometrial cancer within three years of sample collection. The WID-EC test identified women with endometrial cancer with a receiver operator characteristic area under the curve (AUC) of 0.92 (95% CI: 0.88-0.97) in the external set and of 0.82 (95% CI: 0.74-0.89) in the prospective validation set. Using an optimal cutoff, cancer cases were detected with a sensitivity of 86% and a specificity of 90% in the external validation set, and a sensitivity and specificity of 52% and 98% respectively in the prospective validation set. The WID-EC test can identify women with or at risk of endometrial cancer.
| Type: | Article |
|---|---|
| Title: | The WID-EC test for the detection and risk prediction of endometrial cancer |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/ijc.34406 |
| Publisher version: | https://doi.org/10.1002/ijc.34406 |
| Language: | English |
| Additional information: | © 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| Keywords: | DNA methylation, Endometrial cancer, cervical sample, epigenetics, risk prediction |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL EGA Institute for Womens Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL EGA Institute for Womens Health > Womens Cancer |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10162143 |
Archive Staff Only
 |
View Item |
